Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

r, Houston, Texas
  • Abstract 7609, General Poster Session, Lung Cancer – Metastatic Track
  • Sunday, June 6, 2010, 8:00 a.m.-12:00 p.m., S Hall A2

  • Breast Cancer

    • Multivariate Analysis (MVA) of Progression-Free Survival (PFS) in 2 Phase 2b, Multinational, Double-Blind, Randomized, Placebo-Controlled Trials Evaluating Sorafenib Plus Standard Chemotherapy in Patients with HER-2 Negative Locally advanced or Metastatic Breast Cancer.
      • William John Gradishar, M.D., Northwestern University Feinberg School of Medicine, Chicago, Illinois
      • Abstract 1073, General Poster Session, Breast Cancer Track
      • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2
    • A Regional Subgroup Analysis of a Multinational, Double-Blind, Randomized, Placebo Controlled, Phase 2b Study Evaluating Sorafenib (SOR) with Paclitaxel (PAC) in Patients (pts) with Advanced Breast Cancer (BC).
      • Tarini Prasad Sahoo, M.D., Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, India
      • Abstract 1114, General Poster Session, Breast Cancer Track
      • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2
    • Management of Hand-Foot Skin Reaction (HFSR)/Hand-Foot Syndrome (HFS) in SOLTI-0701: A Double-Blind, Randomized Phase 2b Study Comparing Sorafenib vs Placebo in Comb
      '/>"/>

    SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
    2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
    3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
    4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
    5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
    6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
    7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
    8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
    9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
    10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
    11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
    (Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
    (Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
    (Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
    Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
    ... Oct. 23 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) ... Diego on Tuesday, October 28, 2008 at 10:30 a.m. ... and Chief Financial Officer, will,be providing a corporate overview., ... a recording will be made,available following the event. The ...
    ... Sciences,Holdings, Inc. (Nasdaq: ADLS ) a biopharmaceutical company ... in the,therapeutic areas of infection, cancer and respiratory diseases, ... Bank to increase,its line of credit from $4 million ... by 12 months to January 1, 2011. The closing ...
    ... Oct. 23 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... care by developing novel medicines in the areas ... results and,highlights for the third quarter ended September ... progress in both of our hepatitis C,development programs," ...
    Cached Biology Technology:Advanced Life Sciences Completes Debt Transaction 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 8
    (Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
    (Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
    (Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
    Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
    ... the University of California, San Diego (UCSD) Skaggs School ... for developing a human vaccine to prevent against Human ... a type of herpes virus, is the leading viral ... patients with compromised immune systems. The body’s natural ...
    ... the first time anywhere, a researcher at the Hebrew University ... of neurons in the brain of a mammal. , ... Alexander Silberman Institute of Life Sciences at the Hebrew University, ... develop from an undifferentiated cellular sphere into a rich and ...
    ... lethal toxin is revealed today. This toxin is the one real ... kg — the weight of two bags of sugar — is ... of the same toxin are used in medical treatments, one of ... C. botulinum doesn’t have subtle tools to evade our human defences ...
    Cached Biology News:New vaccine prevents CMV infection and disease in mice 2New vaccine prevents CMV infection and disease in mice 3A first -- Hebrew University scientist observes brain cell development in 'real time' 2Genome of Clostridium botulinum reveals the background to world's deadliest toxin 2Genome of Clostridium botulinum reveals the background to world's deadliest toxin 3
    Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
    Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
    Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
    RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: